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 i 
Abstract 
Upon cellular differentiation the late genes of the Human Papillomavirus (HPV) are 
expressed. Recently, the CTCF DNA-binding protein has been found to be transcription 
factor and chromatin insulator.  We examined if CTCF plays a role in viral transcription 
and late gene expression. Through ChIP analysis it was found that CTCF binds to two 
distinct regions of the Bovine Papillomavirus-1 genome.  It was observed that the E2 
protein and CTCF protein interact by co-immunoprecipitation. Using RNA interference, 
the effect of CTCF on viral transcription was examined.  It was shown that E2 and L1 
RNA levels are knocked out with lower levels of CTCF. Further studies should 
investigate if the type of interactions between E2 and CTCF, and the mechanism in which 
CTCF controls viral transcription.  
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1.0 Background 
1.1­ Human Papillomavirus Overview 
HPV is the most frequently spread sexually transmitted disease, although most 
forms are not dangerous there are some high risk forms that can develop into cervical 
cancer, other epithelial cancers, or genital warts (18). Also, high risk HPVs can cause 
head and neck cancer although it is not as common as cervical cancer (16). The 
transformation of HPV-infected cells to cancer is relatively rare, but as of 2006 cervical 
cancer is the fifth deadliest cancer in women worldwide (17). It has also been found that 
in 99.7% of cervical cancer patients there is a presence of HPV DNA, which means that 
HPV infection is necessary for the development of cervical cancer (18). On average, 
genital HPV infections last 12-18 months prior to being cleared by the immune system, 
but the small number of women whose immune systems do not clear the infection are at 
risk for cervical cancer (17). This suggests that HPV is able to overcome the immune 
system’s response. One proposed method of how HPV can surpass the body’s immune 
system is that it modifies the body’s cell-mediated immune responses and it can also alter 
the innate immune system (7). 
Human Papillomaviruses are small, non-
enveloped, icosahedral DNA viruses that induce 
proliferative lesions, and replicate in the squamous 
epithelial cells (6,10). The HPV virion particle 
(Figure 1) is 52 to 55 nm in diameter.  The particle 
Figure 1: Three-dimensional surface display of 
the HPV virion (6).   
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consists of a single molecule of double stranded circular DNA about 8,000 base pairs in 
size, and is contained within a spherical protein coat known as the capsid (10). 
There have been over 100 different types of HPV identified. Different types of 
HPV are classified as either low-risk or high-risk depending on their potential for 
malignant transformation. The low-risk types such as HPV-6 and -11 usually cause 
benign warts and are rarely associated with the formation of cancer. The high-risk HPV 
such as HPV-16, -18, -31, and -45 have been linked to the formation of cervical cancer, 
head and neck cancer, and other genital cancers. The difference in the phenotype of the 
high risk and low risk HPV occur for many different reasons. In high risk HPV there are 
two major promoters, but in low risk there is only one. In the high risk HPV the early 
promoter causes E2-mediated transcription to be repressed causing high levels of the 
oncoproteins E6 and E7.  Also, the different forms of HPV have different genomes, 
where genomes vary in size, composite, and gene organization.  Lastly, for the high risk 
HPV a single promoter is responsible for the expression of E6 and E7 whereas for the 
low risk HPV the E6 and E7 proteins each have an independent promoter (6).  
The genome 
of HPV has roughly 
eight open-reading 
frames (ORFs) 
(Figure 2) (6). The 
viral genes can be 
divided into two 
categories, early and late, depending on their location within the genome, and their order 
Figure 2: The genomes for BPV-1 and the high risk HPV-16 (8). 
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of expression (6,10). In the early stages of infection the E6, E7, E1, and E2 proteins are 
transcribed from the early promoter. During the late stage of the virus high-level 
transcription of E1, E2, E4, E5, and capsid proteins L1 and L2 occurs (6).  The upstream 
regulatory region (URR) regulates early viral transcription. The URR is approximately 
1kb in size and contains binding sites for transcription factors that regulate, induce, or 
repress HPV transcription (6,10). 
The life cycle of HPV is closely associated to epithelial differentiation. HPV 
enters the cells through an unknown receptor and then migrates to the nucleus of the 
cells. It has been shown that HPV can bind and infect a wide variety of cell types (10). 
During the infection of HPV the viral proteins override the cells normal cell cycle that 
takes place in differentiating cells to allow viral progeny to form. Due to the fact that 
basal cells are the only cells that can divide in the squamous epithelium the virus must 
infect the basal cells in a way that allows the virus to thrive (6).  
Certain stages of the HPV life cycle only occur in differentiating squamous 
epithalamium cell such as late gene expression, synthesis of capsid proteins, vegetative 
viral DNA synthesis, and the assembly of virions. This is due to a specific promoter 
which becomes active exclusively in differentiated keratinocytes. The vegetative 
replication of HPV DNA allows the genomes to be generated and packed into virions. 
The mechanism of the vegetative viral DNA replication is still unknown (10).   
The transcription of HPV is complex due to the many promoters located 
throughout the genome (not shown in Figure 2), which cause alternate and multiple 
splicing patterns and differential production of mRNA species in different cells. There 
have been seven different transcriptional promoters identified for bovine papillomavirus 
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(BPV-1), and their locations are shown on the genome (Figure 2). More than twenty 
mRNA species and their putative gene products have been identified (6,10).  
 HPV has three modes of viral DNA replication. The first takes place during the 
initial infection of the basal keratinocytes by the virus, when there is an amplification of 
the viral genome to approximately 50 to 100 copies. The next phase involves genome 
maintenance, which occurs in the dividing basal cells in the lower portion of the 
epidermis. The DNA is then maintained as a stable multicopy plasmid. During this phase 
the viral genome replicates on average once per cell cycle during the S-phase in 
synchrony with the host cell genome, and are then separated evenly into the daughter 
cells. The last type of DNA replication is vegetative DNA replication, which occurs in 
the more differentiated epithelial cells. These cells no longer undergo cellular DNA 
synthesis. The termination of cellular DNA synthesis induces a burst of viral DNA 
synthesis, generating the genomes to be packaged into progeny virions (10). 
In addition to E1, E2, E6, and E7 proteins, the virus is dependent on many host 
cell factors for viral replication including: DNA polymerase α, thymidine kinase, PCNA, 
1506 doi: 10.1111/j.1349-7006.2007.00546.x
© 2007 Japanese Cancer Association
environment suitable for viral DNA replication, which sometimes
induces host cellular DNA synthesis and prevents apoptosis. In
the outer layers of the epithelium, viral DNA is packaged into
capsids and progeny virions are released to re-initiate infection.
Because the highly immunogenic virions are synthesized at the
upper layers of stratified squamous epithelia they undergo only
relatively limited surveillance by cells of the immune system.
In addition, E6 and E7 inactivate interferon (IFN) regulatory
factor (IRF),(7,8) so that HPV viruses can remain as persistent,
asymptomatic infections.
HPV infection and HPV-induced transformation
Cervical cancers originate from the lining of the cervix, the
lower part of the uterus. The squamocolumnar junction, where
the stratified non-keratinizing squamous epithelium from the
exocervix and the columnar epithelium from the endocervix
meet, is the most important cytologic and colposcopic landmark,
as this is highly susceptible to HPV infection and is the site
where more than 90% of lower genital tract neoplasia arises.
Infection with high-risk HPV is associated with cervical
dysplasia or cervical intraepithelial neoplasia (CIN), and
cervical cancers are thought to arise from these lesions after
long persistent infection.(9,10) CIN I (mild dysplasia) and CIN II
(moderate dysplasia) lesions show relatively low levels of
E6 and E7 expression in which the viral genomes replicate
episomally, whereas CIN III (severe dysplasia, carcinoma in
situ) and invasive cancer lesions often display high-level
expression of E6 and E7, in most cases with the integration
of viral DNA into the host cell genome whereby neoplastic
development is believed to be initiated.(11)
Although HPV infections are common and the life-time risk
of infection is approximately 80% for productive women, in
most cases they are resolved spontaneously by an effective
immune response. The ultimate development of cervical cancer
is rarely accompanied by high expression of E6 and E7 proteins.
Thus the authors speculate that the integration of the viral
genome into the host cell is a very rare event, but after it has
happened carcinogenic transformation progresses rapidly
(Fig. 3). However, epidemiological studies and experimental
data indicate that the viral presence is not enough to induce
cervical cancer and additional genetic and epigenetic events are
Fig. 2. Human papillomavirus (HPV) use a unique
strategy for propagation, limited to stratified
flattened epithelial tissue of mucosa and skin.
Initially, HPV must infect stem cells or basal cells of
the tissue where a phase of latent infection is
established in which viral DNA replicate with-
out making virions. In the upper layer, as cells
differentiate, vegetative replication of viral DNA
coordinates with expression of capsid proteins to
make virions that are then freed to search for new
host cells. Expression levels of E6 and E7 in basal
cells are considered to be quite low. However, as
such infections can continue for years and even for
decades, cells may acquire high-level expression of
E6 and E7 through mutations and integration of
the viral genome. Such cells could become
immortal and tumorigenic with further genetic
and epigenetic events.
Fig. 3. E6 and E7 cooperatively function in
the development of cervical cancer. Multistep
carcinogenesis for human papillomavirus (HPV)-
induced cervical cancer. The authors would like to
emphasize that the bottleneck step to cancer is
the overexpression of E6 and E7, which is usually
achieved by accidental integration of a viral
genome into a host chromosome. Once E6 and E7
genes are overexpressed, subsequent events (in
the dark box) might be expected to occur within
a short period of time because E6 and E7 can
cooperatively induce chromosomal instability.
Figure 3: The life cycle of the Human Papillomavirus (12). 
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and many others. HPV also has evolved a mechanism to activate cellular genes necessary 
for replication in the vegetative DNA replication. This is important because most of the 
host cell factors are present only during DNA replication not when the cells are highly 
differentiated (10). 
1.2­ HPV Viral Proteins 
1.2.1­ E6 and E7 Oncoproteins 
 The E6 protein of the high risk forms of HPV contains approximately 150 amino 
acids including four Cys-X-X-Cys motifs, which are responsible for binding zinc 
(6,10,12). The E6 protein is localized to the nucleus and cytoplasm of the infected cells. 
The main function of the E6 protein is interfering with p53 mediated cell cycle regulation 
(12).  p53 is a tumor suppressor that plays an essential role in the cells response to DNA 
damage and other cellular stress by activating several regulators of the apoptotic and 
senescence pathways (5). The E6 protein binds to p53 reducing the steady-state levels of 
p53. The reduction of steady-state levels of p53 allows viral replication and ends the 
transcriptional transactivation of p53 (6,10,12). This means that E6 has an anti-apoptotic 
function. The E6 protein is able to degrade the p53 function by inducing the ubiquitin 
dependent proteolysis of p53 by forming a complex with E6AP, an ubiquitin-protein 
ligase, which then can bind to p53. E6 has also been shown to interact with proteins that 
have PDZ domains, which are involved in cell signaling and cell-cell adhesion. This 
interaction plays a major role in the HPV life cycle because a mutation to the E6-PDZ 
binding domain has shown a reduction in growth, episomal maintenance, and early 
transcription. E6 can also extend the life span of keratinocytes and lead to outgrowth of 
immortalized clones, which are resistant to terminal differentiation.  The E6 protein is 
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also responsible for the activation of telomerase in infected cells, which causes an 
increase of length of the telomeres (30). In normal cells telomeres gradual decrease in 
size that leads to chromosomal instability and cellular senescence and apoptosis (5).   
 The E7 oncoprotein has approximately 98 amino acids and three conserved 
regions, CR1, CR2, and CR3. The CR1 domain is part of the amino terminus, CR2, has 
an LXCXE motif that controls binding of E7 to the retinoblastoma (Rb) tumor suppressor 
protein family, and CR3 consists of two zinc finger motifs (6). A main role of the E7 
protein is the binding and degradation of the Rb proteins (12). The Rb family of proteins 
are major regulators of the cell cycle. When Rb is hypophoshorylated it controls the 
transition of the cell cycle at G1/S phase by binding the E2F family of transcription 
factors. The E2F transcription factors activate the transcription of many cellular 
components during S-phase replication.  The binding of Rb is regulated by two separate 
regions of the protein, the LXCXE motif in CR2 is necessary for the binding of the Rb 
proteins, and the N-terminus has the important residues for the degradation of the Rb 
proteins. The binding and degradation of the Rb proteins by E7 causes the release of the 
E2F complex (6).  E7 also effects the E2F stimulated transcription by interacting with the 
class I histone deacetylases (HDACs). HDACs act as transcriptional corepressors, a 
protein that works with transcription factors to decrease the rate of gene transcription, by 
inducing chromatin remodeling by the deacetylation of histones. E7 binds the HDACs 
indirectly by an interaction that is mediated through sequences in the zinc-finger region. 
The binding of E7 to HDACs has been shown to increase levels of the E2F mediated 
transcription in differentiated cells that causes them to proceed into S-phase.  The 
expression of E7 also causes genomic instability by causing the infected cells to exhibit 
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centrosomal irregularities, such as abnormal number of centromeres. The genomic 
instability is common in many malignancies (6). In the low risk forms of HPV, the E7 
protein binds pRb with 10-fold lower efficiency than in the high risk types. Also, low risk 
forms of HPV E7 are functionally inefficient in cellular transformation (10). 
1.2.2­E1 and E2 Protein  
E1 is the central and essential replication 
factor that serves as the origin recognition protein 
initiating viral DNA replication (25). The E1 
protein has a molecular weight of about 70kDa (6). 
The secondary structures of E1 for both BPV and 
HPV-11 are made up of 36% α-helices, 24% β-
sheets, 31% random coil, and 9% turns.  It has been 
shown that both E1 for HPV and BPV lacking the 
N-terminal region still support viral DNA 
replication indicating the necessary functions for viral replication are located on the C-
terminus (25). The E1 ORF is the largest ORF in the HPV genome and is well conserved 
among all types of HPV, which shows the importance of the function of the E1 protein 
(6, 16). The E1 protein is expressed throughout the HPV life cycle at very low levels, but 
when the late promoter is active the expression of E1 is increased (6,24). The E1 protein 
has DNA dependent ATPase, helicase, and nucleotide-binding activities. The ATP and 
helicase activity plays a role in the origin unwinding fork progression (27). The ATPase 
and helicase activity of E1 is localized to the C-terminus. The ATPase and helicase 
activity of E1 makes it the only papillomavirus protein with enzymatic activity (29,32).  
Figure 4: The secondary structure of BPV-1 
highlighting the HR1 and HR3 domains(24). 
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The E2 protein functions both in viral replication and regulation of HPV 
transcription. The E2 protein has a molecular weight of approximately 50 kDa. E2 
consists of a β-barrel that forms dimeric complexes and binds to DNA (6). The N-
terminus of E2 has a transactivation domain and the C-terminus is involved in the 
interaction with the oncoprotein E1 and DNA binding (11). The URRs (upstream 
regulatory region) of high risk HPV contain four E2 binding sites that have the 
palindromic sequence ACCN6GGT (20).  Three of those sequences are the E1 
recognition sequences at the viral origin, and the fourth site is located near the center of 
the L1 ORF (6). At low levels E2 activates viral transcription, but at high levels it 
represses viral transcription. This suggests that E2 serves as a regulator of the E6 and E7 
proteins mediated cell cycle activities. Therefore, the loss of E2 expression is associated 
with increased cellular proliferation induced by E6 and E7 leading to cervical cancer 
(11). The E2 protein also plays a role in the early promoter expression by altering 
chromatin remodeling through the recruitment of histone acetyltransferases (HATs). 
Once differentiation takes places transcription of the viral genes switches from the E2-
regulated early promoter to the E2 independent late promoter, this results in high levels 
of E1 and E2 transcription leading to viral amplification (6). Also, E2 does not play a 
direct role in the viral DNA replication; it only plays a role in the pre-initiation complex 
(10).  Lastly, E2 has been shown to play a role in episomal maintenance and possibly 
tether viral genomes to mitotic chromosomes during cell division (6).  
1.2.3­L1 and L2 Capsid Proteins 
 L1 is about 55kDa in size, and L2 has a molecule weight of 70kDa (10). The L1 
and L2 capsid proteins are expressed late in the viral life cycle in highly differentiated 
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cells. After amplification HPV genomes are packaged as chromatin into viral capsids 
composed of L1 and L2. HPV virions structure is icosahedral, and entails 360 L1 
monomers assembled into 72 pentameric structures termed capsomeres. Approximately, 
12 copies of the L2 associate with the capsomeres by a domain near the C-terminus of 
L2. The L1 associates with the capsomeres formed in the cytoplasm and then translocate 
through the nuclear pore complex into the nucleus. L2 is translocated separately into the 
nucleus by two nuclear localization signal sequences. The L2 capsid protein may play a 
role in recruiting viral genomes and initiating encapsidation. L2 can bind DNA and 
localize to the ND10 domains, which are nuclear bodies and the major site of DNA 
replication. Therefore, L2 may bind newly replicated viral DNA and recruit L1 to create 
new virions (6). 
1.3­ HPV Late Gene Activation 
The HPV late genes L1 and L2 have been shown to activate only during high 
levels of cellular differentiation, and linked to cellular differentiation for late gene 
expression is the use of a transcription factor to trigger the expression of L1 and L2.  The 
cohesin complex has recently been shown to interact with the E2 viral protein. The 
cohesin complex also associates with the known transcription factor CTCF. For this 
reason it was proposed that the CTCF protein would be a good candidate as the 
transcription factor controlling late gene expression.   
1.3.1­ Cohesin Complex 
One of the most important factors for a virus to survive is its ability to replicate its 
viral genome and distribute it evenly into the host’s daughter cells. The cohesin complex 
is essential for this due to its role in chromosome segregation. Cohesin is a protein 
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Figure 5: Cleavage of cohesin by seperase (21). 
complex that forms a ring around the sister chromatids to hold them together during DNA 
replication at telephase(14, 23). The cohesin protein complex is composed of four 
subunits Smc-1, Smc-3, Scc-1 (Rad-21), and Scc-3. The Smc proteins are heterodimers 
ATPases that are responsible for structural maintenance of the complex (2,28). The 
formation of the ring has the Smc-1 and Smc-3 proteins linked at one end by a hinge 
interaction and by the Scc-1 protein at the other end. The Scc-1 protein holds the cohesin 
complex together (28).  
The cohesin complex forces the sister chromatids to be handled as a pair then 
segregated away from each other. After the chromosomes are properly aligned in the 
mitotic spindle, cohesin is cleaved to allow separation of the sister chromatids into the 
daughter cells. The cleavage of cohesin 
occurs by the cysteine protease, 
separase, at the Scc-1 protein during 
anaphase. Cohesin has also been shown 
to play a role in gene regulation, DNA 
repair, and chromatin structure and development (28).  
 Cohesin contributes to gene regulation by influencing enhancers, silencers, and 
insulators. For example, the cleavage of cohesin is required for establishing silencers and 
it influences the ability of insulators to separate the regions of active and inactive 
chromatin (28). 
1.3.2­ Cohesin and CTCF Association 
 The first connection that was found between cohesin and CTCF was that many of 
the cohesin binding sites that were mapped in the human genome overlap the binding 
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sites of the CTCF protein (8,23). Two of these regions are the H19 imprinting control 
region and the LCR region. Also, it was found that the CTCF and Scc-1 sequences are 
very similar to one another (8,19).  
CTCF is required for the localization of cohesin at its binding sites. This was 
shown by the effect of removing CTCF and the result was disruption of the positioning of 
the Scc-1 and Smc-3 proteins of the cohesin complex (23).  It was revealed that CTCF is 
not required for loading of cohesin onto DNA, showing that both cohesin and CTCF can 
associate with DNA independently. Although CTCF is required for cohesin localization, 
cohesin is not required for CTCF localization (3,14,23).  
Even though cohesin recognizes CTCF for positioning through the genome, it has 
been shown that cohesin can interact with chromatin fibers independently of CTCF. The 
significance of this is that CTCF does not play a role in sister chromatids cohesion, but 
that cohesin could determine the 
function of CTCF at specific sites 
(4,18,23). Specifically, cohesin has 
been shown to be required for CTCF’s 
insulator function (23). A mechanism 
was proposed that cohesin stabilizes 
CTCF chromosome loops during 
chromatin insulation. This was shown by 
the fact that genes within 25 kb of cohesin sites had a higher tendency to be upregulated. 
This mechanism has the CTCF bound to the DNA in a loop, and then the cohesin 
Using this technique, multiple laboratories demonstrated
CTCF-dependent loops in the H19-Igf2 locus in which trans-
criptional enhancers contact the insulator region, preventing
interaction of the enhancers with the Igf2 promoter.(17–19)
CTCF is also required to organize long-range loops between
different CTCF-binding sites in the mouse b globin locus,(20)
and between the XL9 control element and theHLA-DRB1 and
HLA-DQA1 MHCII genes.(21) Strikingly, using 3C and fluo-
rescence in situ hybridization (FISH), CTCF was also found to
mediate interchromosomal interactions between the mouse
Igf2-H19 locus on chromosome 7 and theWsb1-Nf1 locus on
chromosome 11.(22) CTCF also facilitates homologous inter-
actions between X chromosomes that are required for X
inactivation.(23)
It has been proposed that long-range interactions between
different CTCF sites may involve CTCF self-interactions, or
interactions between CTCF and other proteins such as
nucleophosmin,(10) but the finding that cohesin accumulates
at CTCF-binding sites now allows one to speculate that
cohesin stabilizes CTCF-mediated long-range interactions
using mechanisms similar to those by which it holds sister
chromatids together (Fig. 3). Multiple cohesin rings likely bind
to each cohesin-binding region and thus, during G2, it is
possible that some cohesin is diverted from a role in sister
chromatid cohesion to support long-range intrachromosomal
interactions that form looped-out chromosomal domains
(Fig. 3).
Recent evidence from Drosophila is consistent with a
connection between cohesin and insulators in defining func-
tional chromatin domains. Misulovin et al. mapped the binding
of cohesin a d the Nipped-B loading factor throughout the
Drosophila genome, finding that they co-localize and bind
preferentially to actively transcribed regions.(24) An intrigu-
ing correlation with insulators is apparent in the Abd-B gene
that regulates segmental identity during development.
The regulatory sequences flanking Abd-B contain multiple
Figure 2. ACTCF-dependent insulator (In, red box) is positioned between theH19 and Igf2 genes, just upstream ofH19.(10) CTCF binds
on the maternally derived chromosome (!), preventing activation of the Igf2 g ne by an enhancer (En) located downstream ofH19. On the
paternally inherited chromosome ("), the insulator DNA is methylated, which prevents CTCF binding. The insulator is thereby inactivated,
permitting the downstream enhancer to activate Igf2. Wendt et al. found by chromatin immunoprecipitation that cohesin (Rad21) co-
localizes with CTCF at the insulator in HeLa cells (upper graphs), and that reduction of either CTCF or Rad21 in HeLa cells by siRNA
increases Igf2 transcripts and reduces H19 transcripts, indicating that cohesin contributes to insulator activity.(1)
Figure 3. Speculativemodel for howcohesinmight help form
and stabilize CTCF-dependent long-range chromosome loops.
Cohesin positioned by CTCF and not participating in sister
chromatid cohesion could interact with CTCFat other locations
in the chromosome, or even mediate ‘‘cohesion’’ between two
CTCF sites as it does between sister chromatids.
What the papers say
BioEssays 30.8 717
Figure 6: Loop mechanism for CTCF and cohesin 
(19). 
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encircles the two CTCF loops to hold the CTCF to the DNA, similar to how cohesin 
holds sister chromatids together (19).  
1.3.3­E2 Interactions with Cohesin  
 In mitosis the separation of the papillomavirus genes, is mediated by the C-
terminal DNA binding domain of the E2 protein. The E2 protein binds and tethers the 
viral genome to the host cell chromosomes by protein-protein interactions. Those protein-
protein interactions require N-terminal transcactivation domain of E2, which E2 binds 
with the Scc-1 protein of the cohesin complex. The binding appears to be independent of 
any other cellular factors (21).   
1.3.4­CTCF Protein 
 CTCF is a ubiquitously expressed nuclear protein with an 11 zinc-finger DNA-
binding domain. It was first identified by its ability to bind a number of dissimilar 
regulatory sequences in the regions close to the promoters of the chicken, mouse, and 
human MYC oncogenes (1,8). CTCF is a highly conserved protein, between avian and 
mammalian 93% of the amino acids of CTCF are identical, but 100% of the amino acids 
are identical in the 11 zinc-finger region. Also, the ORFs of CTCF have not changed in 
over 300 million years, and are conserved through a variety of species. This indicates that 
the CTCF protein is adapted and has had no environmental need to mutate and change it 
sequence (1,13).    
CTCF is present as a nuclear extract at 130kDa on SDS-PAGE, but the theoretical 
molecular weight is 82kDa. This is because CTCF is encoded in a 4.1kb mRNA, with the 
largest ORF predicting a 728 amino acid protein. Possibilities for this contradiction are: a 
missing exon in the cDNA due to alternative splicing, posttranslational processing, and 
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certain amino acid compositions could lead to CTCF abnormal electrophoretic migration.  
Also, there is a truncated version of CTCF at 70kDa, which represents only the N-
terminal domain of the protein due to premature termination of translation (9). 
1.3.5­CTCF Structure 
 The CTCF protein is organized into three domains: the N-terminal domain, zinc-
finger domain, and the C-terminal 
domain. The N- and C-termini account for 
two-thirds or the protein, but the zinc-
finger domain is where most of the 
functionality of CTCF occurs. The zinc 
fingers of CTCF are capable of binding 
either DNA or proteins (13,19). The 
CTCF zinc fingers are unique in that they 
can bind different DNA sequences by each zinc finger group or one zinc finger motif can 
bind DNA independently while another zinc finger can bind a protein independently.  
The first ten zinc-fingers are approximately 30 residues long containing a pair of cysteine 
residues, which are separated by 12 amino acids from a pair of histidine residues. These 
amino acids are coordinated with zinc to form an ?-helix structure that recognizes DNA. 
The ?-helix structure allows the zinc-fingers to insert into the major groove of the DNA. 
The recognition of the CTCF protein to different DNA sequences is mediated by varying 
zinc-fingers; therefore, certain sets of zinc-fingers are necessary for binding to certain 
sequences of DNA, but are dispensable for binding to a different sequence. Also, not all 
zinc-fingers that bind to DNA behave in a similar manner. For example some zinc-fingers 
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domains. T hese domains are individual protein
modules tha t , when tested as fusion proteins wi th 
a heterologous D N A-binding domain , confer
t ranscr ipt ional repression . Inhibi t ion of
t ranscr ipt ion is media ted by the centra l Z F  domain
and by sequences both N-terminal and C-terminal 
to the Z F  region6,17. Repression by the N-terminal
domain is regula ted in a cel l-type-specific manner17.
Between avian and mammalian C T C F  proteins,
93% of amino acids are ident ical. However, the
ident i ty r ises to 100% for the region containing the
11 Z Fs6. T he fi rst ten Z Fs are typical units of
~30 residues containing a pair of cysteine residues
invariant ly separated by 12 amino acids from the pair
of hist idines. T hese four residues are coordinated
through zinc to form a compact st ructure with a D N A-
recognit ion !-helix. T his type of Z F  inser ts in to the
major groove of D N A to make specific contacts with
nucleot ides by amino acid side chains at posit ions "1,
+2, +3 and +6, marked in F ig. 1c (reviewed in
Refs 18,19). T he 11th C-terminal C2 H C-type Z F  is
structural ly similar to the C2 H C-type Z Fs of the
F r iend of G ATA-1 (F O G) proteins that bind G ATA
proteins using this type of Z F 20.
Combinatorial use of CTCF zinc fingers
Sequent ia l delet ion of each of the C T C F  Z Fs from
either end genera ted a panel of mutant C T C F
proteins for band-shift exper iments to assess Z F
ut i l iza t ion6,21,22. T his approach suggested tha t
recogni t ion by nat ive C T C F  of different D N A
sequences is media ted by varying contr ibut ions of
individual Z Fs6,10,21–23. T hus, cer ta in sets of Z Fs
appear to be necessary for C T C F  binding to one
target sequence, but are dispensable for binding 
to another (F ig. 2). However, due to the possible
in terdependence of D N A-binding proper t ies of the
individual Z Fs, and/or to addi t ional st ructura l
fea tures tha t could be added to the C2 H 2 Z F  fold by
the in ter-finger l in kers (reviewed in Refs 24,25), the
‘missing finger ’ exper iments probably provided an
incomplete picture of the contr ibut ion to target
specifici ty of individual Z Fs tha t usual ly act in the
context of the complete 11 Z F  ar ray. Never theless,
these resul ts suggest tha t each C T C F  Z F  might be
select ively involved in binding to some targets and
dispensible for binding to others.
Co-crystal st ructures of several t ranscr ipt ion
factors with mult iple Z Fs bound to D N A have helped
to understand the posit ioning and nature of amino
acids responsible for folding and stabil i ty of the
C2 H 2 class Z Fs, as well as of amino acids establishing
D N A contacts19,26,27. Recent ly, extended D N A site
recognit ion by mult iple Z Fs was shown in the
co-crystal st ructure of the six Z Fs of T F I I I A bound to
31 bp of target D N A27. Not a l l of the Z Fs that bound to
D N A behaved al i ke. Some Z Fs were posit ioned in the
major groove to contact base pairs, whereas other Z Fs
traversed the D N A minor groove mak ing few or no
contacts with the D N A backbone27.
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(c) Structural features of CTCF and
     tumor-specific amino acid substitutions 
     in zinc fingers
(a) Chicken CTCF genomic locus
(b) Human CTCF genomic locus
Fig. 1. CTCF and its prote in product. Genom ic organ ization of the ch icken (a) and human (b) CTCF
genes. F illed boxes, prote in cod ing exons; open box s, untranslated exons; arrow , transcription
start sites. Estimated sizes of introns are in kilobases. The e leven ZFs of mam ma lian CTCF are
d istributed in exons E2 to E8, w ith severa l ZFs be ing sp lit across ne ighboring exons15. Structure of
the av ian CTCF gene is shown accord ing to Klenova et a l.15. (c) Structura l features of CTCF and
tumor-specific am ino acid substitutions in ZFs. The comp lete am ino acid sequence of the w ild-type
human CTCF prote in shows the DN A-b ind ing doma in , wh ich is composed of ten C2H2-class ZFs
(ZFs 1–10) and one C2HC-class ZF (C-term ina l ZF11). Red , functiona lly sign ificant sites for CKII
phosphory lation7 and the RGRP-type AT-hook motif 30; green , po l II-interacting doma in . Ma jor base-
contacting residues in ZF3 and ZF7 defined by stud ies of co-crysta l structures of mu lti-ZF factors
bound to DN A and tumor-specific m issense mutations characterized by G . F ilippova and co-workers
(unpub lished) are ind icated on the en largements.
Figure 7: Structure of CTCF zinc-fingers (13). 
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will bind to the major groove to contact the base pairs, while others will migrate to the 
minor groove making few or no contacts with the DNA base pairs. It has also been shown 
that the same zinc finger can behave differently when CTCF is bound to certain target 
sequences. When CTCF is bound to DNA both their polypeptides allosterically customize 
their conformation to engage different zinc-fingers, either for making base contacts or to 
make a target-specific surface that determines interactions with other nuclear proteins 
(13). 
 The regions flanking the zinc-finger domain are the N- and C-terminus. The C-
terminus has a role in the trans-repressing function of CTCF, whereas the role of the N-
terminus domain is not as well classified. These domains show no significant similarities 
to any previously described protein modules, except for three short motifs that are all 
located in the C-terminus. The first motif expressed is KRRGRP-type AT-hook that 
possibly has a role in DNA binding and protein-protein interactions in chromatin. 
Another motif that is strictly conserved is the SKKEDSSDSE motif in the trans-repressor 
region. In this region the protein is phosphorylated on four serines by casein kinase II. A 
third motif is located between the AT-hook and phosphorylation sites. This motif 
contains two repeats of the PXXP-signature characteristic of the SH3-domain binding 
proteins (13).  
1.3.6­CTCF Functions 
 CTCF is a versatile protein that has been shown to have many different cellular 
functions. The best described and studied functions of CTCF are its ability to be a 
transcription factor, chromatin insulator protein, and its role in epigenetics and cancer. 
Other areas where CTCF could possibly play a role in are gene activation and as a tumor 
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suppressor (8,13).  
 CTCF was first characterized as a transcription factor by its ability to bind to the 
metazoan silencing elements. For example, binding of CTCF to the promoters and 
upstream silencer elements of the chicken lysozyme gene and the chicken and human 
MYC gene results in transcriptional repression of the lysozyme and MYC gene. Further 
studies of CTCF found that other CTCF target sites identified transcriptional response 
elements that function in gene repression and activation. Also, CTCF shares many 
common traits with enhancers: it independently functions of position and orientation, it 
compromises functional modules that synergize in transcriptional control, and it acts 
directly on a promoter. An example is that CTCF can act as transcription activator or 
repressor on the lysozome gene. CTCF’s role depends on the presence of the thyroid 
hormone receptor, if this hormone is bound along with CTCF it leads to synergistic 
activation of the lysozome gene, but if it is not bound CTCF causes synergistic repression 
of the gene.  CTCF also contains an independent silencing domain that mediates 
transcriptional repression. The discovery of this domain led to the identification of 
CTCF-interacting co-repressors that recruit histone deacetylase (HDAC) activity. 
Silencing by CTCF and its co-repressors could act directly on the transcriptional start 
site. The ability of CTCF to recruit HDACs leads to CTCF inhibiting transcription by, 
interfering with the transcription initiation complex and/or modifying the promoter 
nucleosomes (13). 
 CTCF has a pivotal role in many chromatin insulators, and is the only major 
protein implicated in establishment of insulators in vertebrates. Protein insulators operate 
by blocking the communication between pivotal cis regulatory elements, gene promoters, 
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and enhancers or silencers. Cis-regulatory DNA elements are a region of DNA that 
controls the expression of genes on the same strand. These elements mediate the level of 
gene expression by recruiting trans-acting factors that influence transcription. The 
regulatory elements used for the insulation are often distant from one another on the 
linear genome. This makes the insulators position-dependent, where the insulator must be 
positioned between the enhancer and its target promoter (8). This suggests that the 
insulator prevents propagation of signals along the chromatin fiber without continuously 
engaging enhancer or silencing factors.  CTCF may mediate the chromatin interaction 
without the need of co-factors due to the finding that CTCF can dimerize when bound to 
DNA and connect two separate DNA molecules. An example of CTCF as a chromatin is 
its interaction with the core insulator sequences in vertebrate insulators, β-globin FII 
insulator, Xenopus repeat organizer elements, and the BEAD-A insulator. CTCF flanks 
the entire region of the?-globin gene cluster, and it presumably protects this domain 
from effects of the adjacent regulatory elements (13).  
One of the most characterized interactions of CTCF describes its role in both 
chromatin insulation and epigenetics. CTCF plays a central part in the H19 imprinting 
control region (ICR) where CTCF affects the downstream Igf2 gene. The region is 
maternally unmethylated and paternally methylated. It regulates the expression of the 
maternal allele of the Igf2 gene by blocking the Igf2 promoters and enhancer from 
communicating with each other. CTCF associates only with the maternal unmethylated 
allele of H19 ICR. The CTCF protein prevents the activation of the Igf2 gene in this 
circumstance. When this region is methylated CTCF cannot bind though, allowing the 
Igf2 gene to be expressed.  Also, the loss of imprinting on the H19 and Igf2 locus have 
 17 
been found to cause Beckwith-Wiedemann Syndrome with increased tumor formation 
(1,8,13).   
Due to CTCF’s ability to read epigenetic marks and the common occurrence of 
epigenetic disturbances in cancer, the function of CTCF in cancer has also been studied. 
Gene mutations to CTCF were found in patients with breast, prostates, and Wilm’s 
tumor’s. These mutations were located in the zinc-finger finger region of the protein, 
which affects the binding and interaction of DNA with other genes. Also, in the PXXP 
motif region a common tumor suppressor was found, the MYC-binding protein BIN1.  It 
was shown that if mutations are made to the prolines in this region, it causes the 
elimination of binding to BIN1, and affects the trans-repressing activity of the C-terminus 
region (1,13). 
CTCF is a unique protein with roles in transcription, insulation, tumor 
suppression, and gene activation. All of these roles could be essential in the HPV 
genome. Also, CTCF and cohesin have been shown to interact with one another and be 
necessary for one another to function, and E2 and cohesin have been shown to interact 
within HPV. Therefore, it was examined if CTCF is not only found within the HPV 
genome, but also if it plays a role in late gene expression and viral transcription.  
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2.0 Methods 
 
Tissue Culture: ID13 and A3 BPV transformed cells were grown at 37° C in DMEM 
media with 10% Fetal Bovine Serum and 1% pen-strep.  Cells were grown up to 1.5x106 
cells/plate before harvesting.  After 24 hours cells were harvested using Phosphate 
Buffered Saline (PBS).  
 
Prediction Program: The prediction program “CTCFBSDB: a CTCF binding site 
database for characterization of vertebrate genomic insulators” (22) was used for the 
prediction of CTCF sites in the BPV-1 genome.   
 
Chromatin Immunoprecipitation: Formaldehyde (37%) was added to ID13 plated cells 
in media and were then incubated at 37°C for 10 minutes. Cells were then harvested with 
PBS and protease inhibitors.  Cell pellets were lysed (SDS Lysis Buffer- 5% Tris 1M 
pH=8.1, 2% EDTA, 10% SDS, and protease inhibitors) in 550µL and incubated on ice for 
10 minutes. Samples were sonicated at 30% in 5 second intervals for one minute.  
Samples were then diluted 10 fold  (SDS dilution buffer- 1% of 10% SDS, 11% of 10% 
Triton, 0.04% EDTA, 1.67% of 1M Tris pH=8.1, 3.34% of 5M NaCl and protease 
inhibitors) except for the input which included 100µL of sample and was placed directly 
into -20°C. A bead slurry of 1:2 Protein A to Agarose was made and pre-cleared with the 
cell lysates for half an hour. The sample was then added to a new set of beads along with 
a respective anti-body, CTCF (rabbit polyclonal Millipore), Rad-21 (rabbit polyclonal 
Abcam), II-1 (rabbit polyclonal Androphy Lab), and II-1 Pre-Bleed. These were 
immunoprecipitated overnight at 4°C.  Samples were then washed with Low Salt (1% of 
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10% SDS, 10% of Triton, .4% of 0.5M EDTA, 2% IM Tris pH=8.1, 3% of 5M NaCl), 
High Salt (low salt buffer with 10% 5M NaCl), LiCl, and 2x TE buffers respectively. 
Samples and input were eluted from beads with buffer (10% SDS and 0.084g of Sodium 
Bicarbonate) and NaCL.  Lysates were transferred off the beads. Samples were heated at 
65°C for four hours.  Protein digest was preformed for the samples (EDTA, Tris-HCl 
pH=6.5, and Proteinase K) and incubated for an hour at 45°C. Samples were then 
prepared for PCR using Qiagen PCR clean-up kits. Samples were prepared for 
amplification with Taq polymerase and buffer, 10mM dNTPs, water, and primers that 
flank CTCF prediction sites at 6682 and 3721 (Table 1). 
Table 1: Primers used for ChIP Analysis 
Primer Name  Forward Sequence (5’3’)  Reverse Sequence (5’3’) 
Flanking 6531  TTCAAGCACAGAGGGCATAAGTC  CAAAATGGCTGAGGACGCTG 
Flanking 3682  TCAATGTTTTCTCCTGTATCC  TTACTATTCTCGCTTTGGTGACG 
  
Co-Immunoprecipitation: IP Buffer (20 mM Tris pH=8.1, 125mM KCl, 0.5% Triton, 
20% Glycerol, 10mM NaF, 2mM Na3VO4, 5mM EDTA, 100mM MgCl2, 1x protease 
inhibitors) was added to the plated A3 cells and left at -80°C overnight. Cells were then 
harvested. Lysates were sonicated at 30% for 5 seconds.  A 1:1 solution of sample and IP 
buffer was made with a 10% input. Antibodies were added to sample, CTCF, Rad-21, II-
1, II-1 PB, and Igg (rabbit Sigma). Protein A beads were added and the samples were 
immunoprecipitated overnight. Samples were washed with IP buffer.  2x Laemmli SDS 
Loading Buffer was added to samples and boiled for 10 minutes. Samples were then run 
on a 10% SDS-PAGE gel.   
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RNA interference:  CTCF mouse shRNAs were packaged in a retrovius, pSM2c vector, 
and transformed into E. Coli (UMass Medical Core Facilities).  The bacterial DNA was 
then isolated by Maxi-Prep (Qiagen Kit). A restriction digest was performed for the 
samples using the sites BamHI and EcoR1 enzymes (Promega) to ensure the vector was 
isolated in the bacterial pellets.  The shRNAs were then transfected with lipofectamine 
into ID13 cells in varying concentrations of 0-3µg (Invitrogen). Cells were harvested, and 
a BCA assay was then conducted on the lysates. 20µg were run on an 10% SDS –PAGE 
gel with actin used as the loading control.   
 
Reverse Transcription:  ID13 cells were transfected as previously described with 0µg of 
shRNA, 1µg of shRNA, 1µg of non-silencing shRNA. Cells were then treated for RNA 
isolation using RNAeasy kit (Qiagen). The isolated RNA was then DNA digested 
(Promega 10x buffer, Promega DNase, Water) and incubated at 37°C for half an hour. 
DNase stop solution (Promega) was added and incubated at 65°C for 10 minutes. The 
samples then underwent reverse transcription using Promega ImpropII enzyme and 
buffer, RnasIN, and Random primer.  Samples were then amplified using the previously 
describe PCR master mix with primers designed for E6, E2, and L1.  
Table 2: Primers used for analysis of CTCF knockdown on viral transcription 
 
Primer Name  Forward Sequence (5’3’)  Reverser Sequence (5’3’) 
E2  TGCAGTTGTCTTTGCAGGAG  AGCACCGTTTAGGTTCTGACAT 
E6  ATGGACCTGAAACCTTTTGC  CAGCCTTCCCGAATTACAAC 
L1  GCCTGTTTGTTTCCTGTCATCTG  ATCTCCCTCCAACCCCTGTAAG 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3.0 Results 
3.1­ Location of CTCF binding sites within the BPV Genome 
To determine if CTCF is involved in BPV it was first examined in silco if there 
were any CTCF binding sites on the BPV-1 genome. To accomplish this an online 
prediction program for CTCF binding sites was used (22).  The prediction site is a 
statistical analysis of the core motifs of CTCF that are represented by position weight 
matrices (PWM). The program focuses on the four PWM that provide the strongest range 
of conserved motifs.   
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Two predicted sites were found in the BPV-1 genome, one in the Pre-E5 region 
and the other in the L1 region (Figure 8C). The Pre-E5 region corresponds to the LM7 
PMW and the L1 region is the LM2 PMW. These sequences received high scores of 
10.2766 and for LM7 5.86352 for LM2, where a 3.0 is a suggestive match (Figure 8A). 
The two PMW for BPV-1 were then studied for homology with the actual BPV-1 
sequence.  For LM2 4 of 19 predicted nucleotides were direct matches to the BPV-1 
sequence. The LM7 site had 3 of 20 nucleotides that directly matched the respective 
BPV-1 sequence. Xie et al. examined the properties of the top ten discovered motifs of 
CTCF, which included the LM2 and LM7 motifs. The conserved nucleotides within these 
PMW were mapped, allowing for the creation of a motif profile for LM2 and LM7. LM2 
has 16 conserved nucleotides of the 19 nucleotide motif, and LM7 has 17 conserved 
nucleotides within its 20 nucleotide motif. These conserved nucleotides were then 
compared to the predicted PMW.  The predicted LM2 motif had 16 conserved 
nucleotides of which three were also found within the BPV-1 sequence. The LM7 motif 
had 13 conserved nucleotides, but none were matches to the BPV-1 sequence. (Figure 
8B)     
3.2­CTCF Binding to the BPV­1 DNA 
 As previously shown CTCF was found to bind the BPV genome in silco. The 
CTCF prediction sites were shown to occur in two specific regions, L1 and Pre-E5.  With 
this evidence it was further examined if CTCF binds to the BPV genome within the 
specified regions in vivo. Also, due to the known interaction of CTCF with cohesin and 
E2 with cohesin, it was investigated if E2 and/or Rad-21, a subunit of cohesin, were 
bound to the same regions of the BPV-1 genome. The BPV transformed cells were cross-
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linked with 37% formaldehyde. First, Rad-21 was immunoprecipitated with its specific 
antibody. The DNA was then amplified for two specific genomic locations, L1 and Pre-
E5. For the L1 region Rad-21 was shown to bind to genomic sequence, but it did not bind 
to the Pre-E5 region. Next, CTCF was immunoprecipitated and its DNA amplified for the 
two specific genomic areas. CTCF was found to bind to the L1 and Pre-E5 regions. This 
shows CTCF does bind to genome at both predicted locations. Also, it shows that CTCF 
can bind to the genome independently of the cohesin complex since Rad-21 only bound 
in the L1 region of the virus. Lastly, the E2 protein was immunoprecipitated and its DNA 
amplified in the two separate regions of the genome, L1 and Pre-E5. The E2 protein 
bound to the genome in the L1 region, but not in the Pre-E5 region (Figure 9).  
 
3.3­ Interactions of CTCF and E2  
 Having shown that E2 and CTCF all bind to the L1 region of the BPV-1 genome 
and that CTCF and E2 both interact with the cohesin complex it was examined if the 
CTCF and E2 protein associate with one another. The interactions of E2 and CTCF were 
investigated through co-immunoprecipitation. Two different circumstances were studied: 
one involved the immunoprecipitation of the CTCF protein with its respective antibody 
and the other was involved the immunoprecipitated of the E2 protein. The 
immunoprecipitation are specific for that protein due to the use of its antibody. This 
ensures that only that protein and proteins that associated with it are pulled down into the 
beads. First, the E2 protein was immunoprecipitated and both E2 and CTCF were blotted 
with their respective antibodies. Unfortunately the heavy and light chain backgrounds 
disrupted the bands for the proteins and it could not be clearly determined if both E2 and 
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CTCF was present. Next, CTCF was immunoprecipitated and again both E2 and CTCF 
were blotted with their respective antibodies. This showed that both E2 and CTCF 
interact with one another within the BPV-1 genome even though they are not found to 
bind all the same regions of the genome (Figure 10).  
3.4­ CTCF Effect on Viral Transcription  
As previously shown, CTCF is located on the BPV-1 genome in two distinct 
locations. One of the locations, Pre-E5, is a location that could be responsible for 
regulation of late gene expression. As CTCF has been shown to be a transcription factor 
it was examined if CTCF regulates late gene expression in the virus. Also, the CTCF 
protein was shown to interact with the transcriptional regulator protein E2. This 
interaction led to possibility that CTCF plays a role in viral transcription. Therefore it 
was investigated the affect of CTCF protein knockdowns on viral transcription and late 
gene expression.  
The first step in determining the role of CTCF in viral transcription and late gene 
expression is ensuring that shRNAs could effectively knockdown CTCF levels in vivo. 
The shRNAs work by cutting out the mRNA responsible for the expression of CTCF 
from the cells (Figure 11). In order to package the shRNAs into the cells it was 
genetically engineered into the pSM2c retrovirus vector. The vector was then transformed 
into E. Coli. The DNA was transfected into BPV-1 transformed cells in ranging 
concentrations of 1-3µg. The lysates were then analyzed for effective knockdown of 
CTCF by western blots with actin as a loading control.  The actin levels were not even; 
therefore, the bands were normalized by integrated density on the ImageJ program.  As 
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shown clearly in the bar graphs there was still a significant knockdown observed in the 
cells ranging to near a 50% knockdown of CTCF in the cells (Figure 12).  
Since the CTCF protein was affected by shRNAs, CTCF’s role in viral 
transcription and gene expression could be studied.  This was investigated by using 
shRNAs to knockdown CTCF.  The BPV transformed cells were transfected with 0µg, 
1µg of shRNAs and 1µg of non-silencing shRNAs respectively. The RNA was then 
isolated from the cells. The isolated RNA then underwent a reverse transcription. First, 
the affect of low levels of CTCF on the E6 oncoprotein was examined. It was shown that 
there was little to no change in the RNA levels of E6. If any change occurred with the 
CTCF knockdown it was actually a rise in the E6 levels. Next, influences of the CTCF 
knockdown on E2 RNA levels was examined, and as Figure 13 shows with low levels of 
CTCF the E2 levels were knocked out. Lastly, it was investigated how CTCF knockdown 
would influence L1. As Figure 13 shows the L1 levels were also completely knocked out. 
This result is contrary to the idea that CTCF is regulating late gene expression, but L1 
was also degraded by the non-silencing shRNAs. This could be due to the fact that L1 is 
knocked out due to the small hairpin shape and not the sequence it encodes (Figure 13).  
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Motif PWM  Input Sequence  Motif Sequence  Motif Start 
Location 
Motif 
Length 
Score 
MIT_LM2  BPV‐1 Complete 
Genome 
TTAACAGTGGGGGACAATA  6682  19  5.86352 
MIT_LM7  BPV‐1 Complete 
Genome 
GAACCAGGTGGTGGTGCAGT  3721  20  10.2766 
LM7               
Motif PMW GAA CCA GGT GGT GGT GCA GT 
BPV-1 seq. GAC AAG CAC AAA TAC TGA TC 
        
LM2               
Motif PMW TTA ACA GTG GGG GAC AAT A 
BPV-1 seq. AAT GTA TAC CAT AGA CAT A 
A. 
B. 
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Figure 8: The prediction site provided two possible CTCF binding sites LM2 and LM7. 
These sites both received high scores because anything above a 3.0 is a suggestive match (A).  
These sites are located in the L1 and Pre-E5 regions of the BPV-1 genome respectively (C). 
The predicted sequences were then compared to the equivalent BPV-1 sequence and to the 
common conserved nucleotides where blue is a match to the BPV-1 sequence and bold and 
italics is a match to the conserved nucleotides (B).  
  
 
Figure 9: ChIP analysis was used to determine if CTCF, E2, and cohesin bind to the LM2 
and LM7 regions of the BPV-1 genome. Each ChIP had a 10% input of the entire cross-
linked cellular lysates, and a negative control of Rabbit Igg was used. For the LM2 site E2, 
CTCF, and Rad-21 all were found to bind to the genome.  For the LM7 predicted site only 
CTCF was found on the genome.  
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Figure 10: Co-immunoprecipitation was completed to determine if CTCF and E2 interact 
with one another within the BPV. Both CTCF and E2 were immunoprecipitated with a 10% 
input of total cellular lysate and their respective negative controls, Rabbit Igg and Pre-
bleed. For the CTCF IP both E2 and CTCF were observed on the membrane proving a 
protein-protein interaction. For the E2 IP the heavy and light chain background bands 
interfered in the same area where the protein bands should be seen.  
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Figure 11: Process of how shRNAs work to knockdown expression of proteins within 
systems. The shRNA is processed by the DICER complex, which prepares it for the RISC 
complex. The RISC complex unwinds the RNA to activate it, and it guides it through until it 
recognizes a target sequence. Upon recognition of a target sequence the mRNA is cut out 
preventing it from being expressed.  
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Figure 12: shRNA knockdown of CTCF levels in BPV transformed cells. The blots show the 
different concentration dosing of the shRNAs, 0-3µg. The actin levels were low for the 
loading control; therefore, blots were normalized by integrated density. The graphs 
correspond to the normalization values of the shRNA knockdown, which shows successful 
knockdown to approximately 50%.   
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Figure 13: Reverse Transcription of CTCF shRNAs transfected cells were examined for its 
affect on viral transcription.  The BPV genome was used as a PCR positive control and 
water was used a PCR negative control. The lanes correspond to 0µg, 1µg, of CTCF 
shRNAs and 1µg of non-silencing shRNAs respectively. With low levels of CTCF both E2 
and L1 were knocked out where E6 levels possibly rose. Also, L1 levels were affected by the 
non-silencing shRNAs leading to a possible influence of the shRNA shape on L1.  
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4.0 Discussion 
 
CTCF has been shown in many different systems to play a role as a transcription 
factor and/or a chromatin insulator. CTCF has been shown to associate with the cohesin 
complex, and the cohesin complex has recently been revealed to interact with the E2 viral 
protein of HPV.   This study was the first to find that the CTCF protein associates with 
HPV.  
The first part of this study showed that CTCF has possible binding sites in the 
BPV-1 genome in silico (Figure 8A-C). The predicted site provided guidance on where to 
look for possible CTCF sites in vivo, but it doesn’t mean that those are the only possible 
CTCF binding sites within the BPV-1 genome. It is possible that it binds to many other 
locations within the genome or that within that one region it could bind numerous times. 
Therefore, CTCF binding sites should be mapped throughout the genome this would 
provide us with a better understanding of where CTCF binds and other possible 
mechanisms for the protein.  
 The predicted sites in the L1 and Pre-E5 regions were then examined in vivo. 
These sites were examined for the binding of the Rad-21 protein, subunit of cohesin, and 
the E2 viral protein. It was shown that for L1 CTCF, E2, and Rad-21 all bind but for Pre-
E5 only CTCF bound (Figure 9). This is interesting because it provides the suggestion 
that CTCF has two independent functions or mechanisms within the genome. The Rad-21 
protein has been shown to be necessary for CTCF’s insulator function. The E2 protein 
has been shown to associate with the cohesin complex throughout the cell cycle, 
providing evidence E2 is essential for cohesin role in gene regulation.  Also, E2 is 
responsible for transcriptional repression of many viral proteins, which could aid in the 
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insulation process for CTCF. Therefore, it is has been presumed that E2 and cohesin are 
important for the insulation function of CTCF.  This provides significant evidence of 
CTCF acting as an insulator in the L1 region and not in the Pre-E5 region. The role of 
CTCF acting independently in the Pre-E5 region would need to be further examined due 
to the fact CTCF is a versatile protein with a range of functions.  
The CTCF protein was also found to associate with the viral protein E2 (Figure 
10).  This is interesting because as previously stated E2 did not bind to the Pre-E5 region 
but CTCF did.  Therefore this means that although the proteins do associate it is not 
always the case. This provides further evidence that although the proteins do interact it 
could be just for certain viral functions, such as the previously described insulation.  
Also, due to CTCF known roles in transcription and E2 acting as the viral protein 
responsible for transcription it is probable that CTCF plays a role in the HPV 
transcription.  This could mean that only when CTCF is affecting viral transcription, such 
as chromatin insulation, do the CTCF and E2 protein interact with each other. The reason 
this is plausible that the interactions could occur only at specific locations is due to the 
fact the CTCF’s zinc fingers are do unique. The zinc fingers are able to allosterically 
change for specific sequences. This could mean that when CTCF is bound to certain 
genomic regions its binding region for E2 is experiencing a conformational changed and 
the binding can’t occur, or it could work the other way so that when bound to E2 the zinc 
fingers are in a conformation that the CTCF protein can only bind to distinct genomic 
regions. Although, if E2 directly binds to CTCF or the association is by an indirect 
mechanism stills needs to investigated.  
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With the ability to lower levels of CTCF through shRNA transfection the role of 
CTCF in late gene expression was studied (Figure 12-13). With the knockdown of CTCF 
levels, L1 levels were knocked out. This is contradictory to the idea of CTCF as an 
insulator for late gene expression, which would have shown an increase in L1 with CTCF 
knockdown. This is further contradicted by the presumption that for CTCF to be able to 
function as an insulator both Rad-21 and E2 must be present, but in the Pre-E5 area that 
precedes the late genes, only CTCF was bound to the genome.  Another issue is that L1 
was also affected by the non-silencing shRNAs. This could mean that the shape of the 
shRNA degrades L1 independently of the sequence of the shRNA. Therefore, a further 
study needs to pursue if the small hairpin shape of the shRNAs affect L1 levels 
independently of their sequence. 
 CTCF ‘s role in viral transcription was also examined through shRNA 
transfection. When CTCF levels were lowered E2 was knocked out where E6 levels rose. 
This is because E2 controls the levels of E6, so with high levels of E2 the E6 protein is 
regulated but with low levels of E2 the E6 is expressed in high levels.  A possible reason 
for this is CTCF is necessary for E2 transcription and possibly an enhancer for E2. The 
reason CTCF can be an enhancer for E2 is because enhancers can act independently of 
their location. Therefore, in the Pre-E5 region where only CTCF is bound it could be 
acting with the E2 promoter for transcription. This it still a preliminary mechanism that 
needs to be further studied for how CTCF and E2 associate during viral transcription. 
A mechanism has been proposed for CTCF’s function in the L1 region, and it 
entails CTCF insulating anti-sense transcription of the virus. This mechanism has 
significant evidence starting with the binding of both E2 and Rad-21 in the L1 region, 
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which as previously discussed could be vital for CTCF chromatin insulation. Therefore it 
is possible that when the CTCF levels are low the virus undergoes anti-sense 
transcription, which leads to the pKR cellular death pathway. This could also explain the 
knockout of L1 when there are low levels of CTCF because the anti-sense transcription 
would lead to rapid degradation of L1.  A cellular death assay should be completed to see 
the affect of shRNA CTCF knockdown on the cells. This mechanism provides an 
explanation for the role of CTCF in the L1 region taking into account all of the findings 
of this study, but it still needs to be further examined.  
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